With new guidance, treatment pathways, and medical advances emerging on a regular basis, the pursuit of knowledge and innovation is a never-ending process for healthcare providers.
For pharmaceutical companies and other healthcare stakeholders, it is imperative that they understand how patient experience and input needs to be captured, contextualised, and applied to t
In a time of increasing cost pressures, limited resource capacity, and heightened demand for new treatments, Health Technology Assessments (HTAs) play a vital role in evaluating whether new
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.